On Jun 29, 2018 34.99 % to Target, Endo International (NASDAQ:ENDP) Stock “Buy” Rating Reconfirmed by B. Riley FBR.

June 29, 2018 - By Brenda Gibbons

Endo International plc (NASDAQ:ENDP) Corporate Logo

During 2018 Q1 the big money sentiment decreased to 1.07. That’s change of 0.06, from 2017Q4’s 1.13. 25 investors sold all, 70 reduced holdings as Endo International plc ratio dropped. 69 grew holdings while 33 funds acquired holdings. Funds hold 213.17 million shares thus 4.61% more from 2017Q4’s 203.77 million shares.

Connor Clark And Lunn Inv Limited has 5.01M shs. Tctc Ltd has 36,194 shs for 0.01% of their capital. New Mexico Educational Retirement Board reported 0.01% of its capital in Endo International plc (NASDAQ:ENDP). California State Teachers Retirement Systems invested 0% of its capital in Endo International plc (NASDAQ:ENDP). Sei Invests holds 1,936 shs. Gotham Asset Limited Liability reported 23,666 shs stake. Texas Permanent School Fund has 0.01% invested in Endo International plc (NASDAQ:ENDP) for 133,068 shs. Massachusetts Finance Services Ma owns 153,610 shs or 0% of their US capital. Vanguard Group Inc has 0% invested in Endo International plc (NASDAQ:ENDP) for 17.24 million shs. River & Mercantile Asset Mngmt Ltd Liability Partnership owns 467,733 shs or 0.32% of their US capital. Raymond James Fincl Advsr holds 0% or 25,109 shs. Moreover, Profund Advsrs Ltd Liability Com has 0.01% invested in Endo International plc (NASDAQ:ENDP) for 25,970 shs. Royal Bank & Trust Of Canada has invested 0% in Endo International plc (NASDAQ:ENDP). Commonwealth Of Pennsylvania Pub School Empls Retrmt System invested 0% of its capital in Endo International plc (NASDAQ:ENDP). Riverhead Cap Mngmt Ltd Liability Company holds 41,218 shs.

Reiterated Endo International (NASDAQ:ENDP) Rating.

New York: On Thursday morning, analysts note was sent to investors of Endo International (NASDAQ:ENDP). Its “Buy” Rating maintained by Analysts at B. Riley FBR. Stock analysts have price target of $13 which indicates 34.99 % upside potential on firm’s stock.

Endo International plc (NASDAQ:ENDP) Ratings Coverage

A total of 11 analysts rate Endo International (NASDAQ:ENDP) as follows: 3 “Buy”, 8 “Hold” and 0 “Sell”. Тherefore 27% are bullish. (NASDAQ:ENDP) has 14 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Friday, February 23 Barclays Capital maintained Endo International plc (NASDAQ:ENDP) rating. Barclays Capital has “Equal-Weight” rating and $10 target. In Wednesday, February 21 report Canaccord Genuity maintained it with “Hold” rating and $7 target. In Monday, February 26 report JMP Securities downgraded the stock to “Market Perform” rating. The company rating was initiated by FBR Capital on Tuesday, February 13. On Wednesday, February 28 the rating was maintained by William Blair with “Hold”. On Wednesday, February 28 the rating was downgraded by Gabelli to “Hold”. The stock rating was maintained by BMO Capital Markets with “Market Perform” on Monday, March 5. On Friday, January 19 the rating was maintained by Mizuho with “Buy”. On Wednesday, June 27 the stock of Endo International plc (NASDAQ:ENDP) earned “Buy” rating by Citigroup. On Tuesday, January 2 the firm has “Hold” rating given by Stifel Nicolaus.

Ticker’s shares touched $9.63 during the last trading session after 2.03% change.Endo International plc has volume of 3.02 million shares. Since June 29, 2017 ENDP has declined 51.05% and is downtrending. ENDP underperformed by 63.62% the S&P 500.

On August, 14 is awaited Endo International plc (NASDAQ:ENDP)’s earnings report, as reported by RTT. earnings per share of $0.54 is 41.94 % down from 2017’s $0.93 EPS. If earnings per share of $0.54 is announced the profit of ENDP could be $120.84M giving it 4.46 P/E. Wall Street now sees -19.40 % negative EPS growth despite Endo International plc last quarter’s EPS of $0.67.

Endo International plc, a specialty pharmaceutical company, makes and sells generic and branded pharmaceuticals in the United States, Canada, and internationally.The firm is valued at $2.16 billion. The firm operates through three divisions: U.S.Currently it has negative earnings. Generic Pharmaceuticals, U.S.

For more Endo International plc (NASDAQ:ENDP) news brought out briefly go to: Seekingalpha.com, Streetinsider.com, Fool.com, Benzinga.com or Profitconfidential.com. The titles are as follows: “Buy Alibaba – Cramer’s Lightning Round (6/12/18)” brought out on June 13, 2018, “Endo (ENDP) Reports Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement …” on June 11, 2018, “Why Endo International plc Rocketed Higher Today” with a publish date: June 06, 2018, “Endo Wins Citi Upgrade On Positive Catalysts, Cellulite Treatment Opportunity” and the last “These Indications Suggest That ENDP Stock Has Finally Found a Bottom” with publication date: June 14, 2018.

Endo International plc (NASDAQ:ENDP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: